Income Statement
BIONEXUS GENE LAB CORP
BGLC
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY |
|---|---|---|---|---|---|---|
|
Revenue
|
9.51 | 9.77 | 10.93 | 13.36 | 11.39 | 0.13 |
|
Cost of Revenue
|
8.22 | 8.44 | 9.67 | 11.17 | 9.67 | -0.07 |
|
Gross Profit
|
1.29 | 1.33 | 1.26 | 2.19 | 1.72 | 0.06 |
|
Operating Expenses
|
-0.37 | 4.41 | 1.73 | 1.20 | 1.33 | -0.36 |
|
Research & Development
|
0.05 | - | - | - | - | - |
|
Selling, General & Administrative
|
2.03 | 4.41 | 1.73 | 1.20 | 1.33 | -0.36 |
|
Other Operating Expenses
|
- | - | - | - | - | - |
|
Operating Income
|
1.66 | -3.08 | -0.47 | 0.99 | 0.39 | 0.41 |
|
Non-Operating Income
|
3.25 | -0.47 | -0.17 | - | - | - |
|
Interest Income
|
0.15 | - | - | - | - | - |
|
Interest Expense
|
- | 0.01 | - | - | - | - |
|
Other Non-Op Income / Expense
|
2.07 | - | - | - | - | 0.03 |
|
Income Before Tax
|
-0.20 | -0.23 | -0.30 | - | - | - |
|
Income Tax Expense
|
0.00 | 0.02 | 0.05 | - | - | 0.02 |
|
Non-Controlling Interest
|
- | - | - | - | - | - |
|
Net Income
|
-1.60 | -2.63 | -0.36 | 0.75 | 1.09 | -0.25 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY |
|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - |
|
EBITDA
|
1.66 | -3.08 | -0.47 | 0.99 | 0.39 | 0.45 |
|
Earnings Per Share (Basic)
|
- | - | - | - | - | - |
|
Diluted EPS
|
-0.09 | - | - | - | - | - |
|
Weighted Average Shares
|
- | - | - | - | - | - |
|
Diluted Weighted Avg Shares
|
17.82 | - | - | - | - | - |
|
Comprehensive Income
|
-1.48 | -2.90 | -0.66 | 0.52 | 1.24 | -0.24 |